Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been assigned an average rating of “Hold” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $16.57.

Several analysts recently weighed in on YMAB shares. BMO Capital Markets lifted their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Canaccord Genuity Group lifted their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. Wedbush restated an “outperform” rating and issued a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Finally, HC Wainwright lifted their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 6th.

Y-mAbs Therapeutics Trading Down 0.6 %

NASDAQ:YMAB opened at $17.15 on Friday. Y-mAbs Therapeutics has a twelve month low of $4.60 and a twelve month high of $20.90. The company has a market cap of $752.42 million, a price-to-earnings ratio of -35.00 and a beta of 0.78. The stock has a fifty day simple moving average of $15.71 and a 200-day simple moving average of $10.92.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.17. The business had revenue of $23.36 million during the quarter, compared to the consensus estimate of $21.72 million. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. As a group, equities research analysts predict that Y-mAbs Therapeutics will post -0.43 EPS for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, SVP Vignesh Rajah sold 1,711 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the transaction, the senior vice president now directly owns 33,889 shares of the company’s stock, valued at approximately $560,185.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 21.50% of the stock is owned by insiders.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Y-mAbs Therapeutics in the fourth quarter valued at about $34,000. Tower Research Capital LLC TRC increased its holdings in Y-mAbs Therapeutics by 345.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock worth $46,000 after buying an additional 5,185 shares during the period. SG Americas Securities LLC purchased a new position in Y-mAbs Therapeutics during the 3rd quarter worth approximately $100,000. Bailard Inc. acquired a new stake in Y-mAbs Therapeutics during the 4th quarter valued at approximately $115,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Y-mAbs Therapeutics by 4.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock valued at $178,000 after acquiring an additional 1,089 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.